{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:01:51Z","timestamp":1790128911064,"version":"4.0.1"},"reference-count":113,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The pyrazole nucleus has long been known as a privileged scaffold in the synthesis of biologically active compounds. Within the numerous pyrazole derivatives developed as potential drugs, this review is focused on molecules characterized by a urea function directly linked to the pyrazole nucleus in a different position. In the last 20 years, the interest of numerous researchers has been especially attracted by pyrazolyl-ureas showing a wide spectrum of biological activities, ranging from the antipathogenic activities (bacteria, plasmodium, toxoplasma, and others) to the anticarcinogenic activities. In particular, in the anticancer field, pyrazolyl-ureas have been shown to interact at the intracellular level on many pathways, in particular on different kinases such as Src, p38-MAPK, TrKa, and others. In addition, some of them evidenced an antiangiogenic potential that deserves to be explored. This review therefore summarizes all these biological data (from 2000 to date), including patented compounds.<\/jats:p>","DOI":"10.3390\/molecules25153457","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T12:15:38Z","timestamp":1596111338000},"page":"3457","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Pyrazolyl-Ureas as Interesting Scaffold in Medicinal Chemistry"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2575-7726","authenticated-orcid":false,"given":"Chiara","family":"Brullo","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Section of Medicinal Chemistry, University of Genoa, Viale Benedetto XV 3, I-16132 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4032-323X","authenticated-orcid":false,"given":"Federica","family":"Rapetti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Section of Medicinal Chemistry, University of Genoa, Viale Benedetto XV 3, I-16132 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Bruno","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Section of Medicinal Chemistry, University of Genoa, Viale Benedetto XV 3, I-16132 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ejmech.2014.11.059","article-title":"Recent advances in bioactive pyrazoles","volume":"97","author":"Kucukguzel","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_2","unstructured":"Behr, L.C., Fusco, R., and Jarboe, C.H. (1967). The Chemistry of Heterocyclic Compounds Pyrazoles, Pyrazoline, Pyrazolidines, Indazoles and Condensed Rings, Interscience Publisher."},{"key":"ref_3","unstructured":"Gilchrist, T.L. (1992). Heterocyclic Chemistry, Longman Scientific & Technical Publisher."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103470","DOI":"10.1016\/j.bioorg.2019.103470","article-title":"Overview of recent developments of pyrazole derivatives as an anticancer agent in different cell line","volume":"97","author":"Bennania","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejmech.2014.07.102","article-title":"Progress of the synthesis of condensed pyrazole derivatives (from 2010 to mid- 2013)","volume":"85","author":"Meng","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ejmech.2014.12.023","article-title":"Recent advanced in bioactive systems containing pyrazole fused with a five membered heterocycle","volume":"97","author":"Raffa","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"622","DOI":"10.2174\/0929867323666161129124915","article-title":"Ureas: Applications in Drug Design","volume":"24","author":"Jagtap","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.2174\/0929867323666160411142532","article-title":"Diaryl Urea: A Privileged Structure in Anticancer Agents","volume":"23","author":"Garuti","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1021\/jm101541x","article-title":"Ureido-Substituted Benzenesulfonamides Potently Inhibit Carbonic Anhydrase IX and Show Antimetastatic Activity in a Model of Breast Cancer Metastasis","volume":"54","author":"Supuran","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/jcc.23335","article-title":"Binding affinity of substituted ureido-benzenesulfonamide ligands to the carbonic anhydrase receptor: A theoretical study of enzyme inhibition","volume":"34","author":"Sahu","year":"2013","journal-title":"J. Comput. Chem."},{"key":"ref_11","unstructured":"Li, S., Zheng, Z., Tao, X., Wang, L., Zhou, X., Chen, W., Zhong, W., Xiao, J., Xie, Y., and Li, X. (2016). 4-Methyl-1H-diaryl Pyrazole Derivative as Cannabine Type I Receptor Inhibitor and Its Preparation. (Application No. 2016184310 A1 20161124), WO Patent."},{"key":"ref_12","unstructured":"Makriyannis, A., Liu, Q., and Thotapally, R. (2006). Preparation of Arylpyrazolecarboxamides as CB1 Cannabinoid Receptor Antagonists. (Application No. 20060100208 A1 20060511), U.S. Patent."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1007\/s10593-014-1587-z","article-title":"Polyfunctional Pyrazoles. 9*. Synthesis of 1-Alkyl(Aryl)-3-[4-(Hydroxymethyl)-1H-Pyrazol-3-Yl]ureas","volume":"50","author":"Bratenko","year":"2014","journal-title":"Chem. Heterocyc. Compd."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8849","DOI":"10.1073\/pnas.96.16.8849","article-title":"Potent urea and carbamate inhibitors of soluble epoxide hydrolases","volume":"96","author":"Morisseau","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1124\/dmd.115.063339","article-title":"The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: Drug metabolism to therapeutics for chronic pain","volume":"43","author":"Kodani","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"ref_16","unstructured":"Hammock, B.D., Kim, I.-H., Morisseau, C., Watanabe, T., and Newmann, J.W. (2004). Improved Inhibitors for the Soluble Epoxide Hydrolase. (Application No. 2004\/089296 A2), WO Patent."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10593-019-02428-2","article-title":"Synthesis and properties of 1-[(adamantan-1-yl)methyl]-3-pyrazolyl ureas","volume":"55","author":"Danilov","year":"2019","journal-title":"Chem. Heterocycl. Compd."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1021\/jm2001376","article-title":"Synthesis and Structure Activity Relationship Studies of Urea-Containing Pyrazoles as Dual Inhibitors of Cyclooxygenase-2 and Soluble Epoxide Hydrolase","volume":"54","author":"Hwang","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/ardp.19973300704","article-title":"Synthesis of N-aryl-N\u2032-heteroaryl-substituted urea and thiourea derivatives and evaluation of their anticonvulsant activity","volume":"330","author":"Heinisch","year":"1997","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/phrs.1997.0250","article-title":"Anticonvulsant activity of thioureido derivatives of acetophenone semicarbazone","volume":"37","author":"Pandeya","year":"1998","journal-title":"Pharmacol. Res."},{"key":"ref_21","first-page":"490","article-title":"Ureylene anticonvulsants and related compounds","volume":"55","author":"Dimmock","year":"2000","journal-title":"Pharmazie"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejps.2005.05.005","article-title":"Synthesis and biological evaluation of new N-substituted-N\u2032-(3,5-di\/1,3,5-trimethylpyrazole-4-yl)thiourea\/urea derivatives","volume":"26","author":"Kaymakcioglu","year":"2005","journal-title":"Eur. J. Pharmac. Sci."},{"key":"ref_23","unstructured":"Clare, M., Fletcher, T.R., Hamper, B.C., Hanson, G.A., Heier, R.F., Huang, H., Lennon, P.J., Oburn, D.S., Reding, M.T., and Stealey, M.A. (2005). Preparation of Substituted Pyrazole Ureas for the Treatment of Inflammation. (Application No. 2005037797 A1 20050428), WO Patent."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd1279","article-title":"The IKK NF-kappa B system: A treasure trove for drug development","volume":"3","author":"Karin","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_25","unstructured":"Baxter, A., Brough, S., Faull, A., Johnstone, C., and Mcinally, T. (2001). Heteroaromatic Carboxamide Derivatives and their Use as Inhibitors of the Enzyme IKK-2. (Application No. 01\/58890 Al PCTISE01\/00248), WO Patent."},{"key":"ref_26","unstructured":"Sharma, R., Jain, A., Sahu, B., Singh, D., and Mali, S. (2014). Preparation of Heterocyclyl Compounds as Inhibitors of IL-17 and TNF-\u03b1 for the Treatment of Inflammatory Diseases and Autoimmune Disorders. (Application No. 2014181287 A1 20141113), WO Patent."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.1073\/pnas.1305378110","article-title":"Structure\u2013kinetic relationship study of CDK8\/CycC specific compounds","volume":"110","author":"Schneider","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cmdc.201800559","article-title":"Discovery of CDK8\/CycC Ligands with a New Virtual Screening Tool","volume":"14","author":"Chen","year":"2019","journal-title":"ChemMedChem"},{"key":"ref_29","unstructured":"Flynn, D.L., Petillo, P.A., Kaufman, M.D., and Patt, W.C. (2008). Preparation of Heterocyclic Ureas as Kinase Inhibitors Useful for the Treatment of Proliferative Diseases. (Application No. 2008033999 A2 20080320), WO Patent."},{"key":"ref_30","unstructured":"Flynn, D.L., Petillo, P.A., Kaufman, M.D., and Patt, W.C. (2009). Preparation of Heterocyclic Ureas as Kinase Inhibitors Useful for the Treatment of Proliferative Diseases. (Application No. 20090099190 A1 20090416), U.S. Patent."},{"key":"ref_31","unstructured":"Flynn, D.L., Kaufman, M.D., Patt, W.C., and Petillo, P.A. (2008). Preparation of Heterocyclic Ureas as Kinase Inhibitors Useful for the Treatment of Proliferative and Inflammatory Diseases. (Application No. 2008034008 A2 20080320), WO Patent."},{"key":"ref_32","unstructured":"Flynn, D.L., Petillo, P.A., Kaufman, M.D., and Patt, W.C. (2012). Preparation of Dihydropyridopyrimidinyl, Dihydronaphthyidinyl and Related Compounds Useful as Kinase Inhibitors for the Treatment of Proliferative Diseases. (Application No. 8188113 B2 20120529), U.S. Patent."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.heares.2006.09.008","article-title":"Blocking c-Jun-N-terminal kinase signaling can prevent hearing loss induced by both electrode insertion trauma and neomycin ototoxicity","volume":"226","author":"Eshraghi","year":"2007","journal-title":"Hear Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8596","DOI":"10.1523\/JNEUROSCI.23-24-08596.2003","article-title":"A Peptide Inhibitor of c-Jun N-Terminal Kinase Protects against Both Aminoglycoside and Acoustic Trauma-Induced Auditory Hair Cell Death and Hearing Loss","volume":"23","author":"Wang","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_35","unstructured":"Feng, Y., LoGrasso, P., Zheng, K., and Park, C.M. (2015). Preparation of Substituted Pyrazolylbenzamides as JNK Kinase Inhibitors. (Application No. 2015084936 A1 20150611), WO Patent."},{"key":"ref_36","unstructured":"Cherrier, M.P., Parmantier, E., Minoux, H., Clerc, F., Angouillant-Boniface, O., Brollo, M., and Schio, L. (2008). Pyrazolylbenzimidazole Derivative, their Preparation, Compositions Containing them and their Use for Treating Diseases, Especially Cancer. (Application No. 2008003857 A1 20080110), WO Patent."},{"key":"ref_37","first-page":"86","article-title":"A review of p38 kinase inhibitors as anti-inflammatory drugs targets","volume":"2","author":"Swapna","year":"2010","journal-title":"Int. J. Pharm. Technol. (IJPT)"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.chembiol.2006.05.015","article-title":"A general strategy for creating \u201cinactive-conformation\u2019\u2019 abl inhibitors","volume":"13","author":"Barun","year":"2006","journal-title":"Chem. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0960-894X(00)00270-5","article-title":"Discovery of a new class of p38 kinase inhibitors","volume":"10","author":"Dumas","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0960-894X(00)00272-9","article-title":"1-Phenyl-5-pyrazolyl ureas: Potent and selective p38 kinase inhibitors","volume":"10","author":"Dumas","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0960-894X(00)00574-6","article-title":"p38 Kinase Inhibitors for the Treatment of Arthritis and Osteoporosis: Thienyl, Furyl, and Pyrrolyl Ureas","volume":"11","author":"Redman","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0960-894X(02)00238-X","article-title":"Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor","volume":"12","author":"Dumas","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_43","unstructured":"Cirillo, P.F., Gilmore, T.A., Hickey, E.R., Regan, J.R., and Zhang, L.-H. (2000). Preparation of Aromatic Heterocyclic Ureas as Antiinflammatory Agents. (Application No. 2000043384 A1 20000727), WO Patent."},{"key":"ref_44","unstructured":"Zhang, L.-H., and Zhu, L. (2001). Novel Process for Synthesis of Heteroaryl-Substituted Ureas. (Application No. 2001004115 A2 20010118), WO Patent."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nsb770","article-title":"Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site","volume":"9","author":"Pargellis","year":"2002","journal-title":"Nat. Struct. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1021\/jm020057r","article-title":"Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate","volume":"45","author":"Regan","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4110\/in.2013.13.6.283","article-title":"BIRB 796 has Distinctive Anti-inflammatory Effects on Different Cell Types","volume":"13","author":"Soyoon","year":"2013","journal-title":"Immune Netw."},{"key":"ref_48","unstructured":"(2020, February 05). Available online: https:\/\/www.clinicaltrials.gov\/."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1039\/b611493h","article-title":"Microwave-assisted Synthesis of N-pyrazole Ureas and the p38alpha Inhibitor BIRB 796 for Study into Accelerated Cell Ageing","volume":"4","author":"Bagley","year":"2006","journal-title":"Org. Biomol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10822-006-9092-9","article-title":"Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: A molecular modeling study","volume":"21","author":"Kulkarni","year":"2007","journal-title":"J. Comput.-Aided Mol. Des."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7772","DOI":"10.1021\/jm3008008","article-title":"Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo [1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor","volume":"55","author":"Toru","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jat.1622","article-title":"A possible mechanism for hepatotoxicity induced by BIRB-796, an orally active p38 mitogen-activated protein kinase inhibitor","volume":"31","author":"Shunsuke","year":"2011","journal-title":"J. Appl. Toxicol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/molecules19022004","article-title":"Synthesis and biological evaluation of chromenylurea and chromanylurea derivatives as anti-TNF-\u03b1 agents that target the p38 MAPK pathway","volume":"19","author":"Li","year":"2014","journal-title":"Molecules"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1080\/00397910902883603","article-title":"Short Synthesis of 1-(3-tert-Butyl-1-phenyl-1H-pyrazol-5-yl)-3-(5-(2-morpholinoethoxy)-2H-chromen-8-yl) Urea Derivatives","volume":"39","author":"Li","year":"2009","journal-title":"Synth. Commun."},{"key":"ref_55","unstructured":"Flynn, D.L., and Petillo, P.A. (2005). Preparation of 1-pyrazolyl-3-phenylurea p38 MAP Kinase Inhibitors as Antiinflammatory Medicaments. (Application No. 20050288286 A1 20051229), U.S. Patent."},{"key":"ref_56","unstructured":"Flynn, D.L., and Petillo, P.A. (2006). Preparation of Pyrazolyl aryl Ureas as Modulators of the Protein Kinase Activation State for Treatment of Inflammation and Hyperproliferative Diseases. (Application No. 2006081034 A2 20060803), WO Patent."},{"key":"ref_57","unstructured":"Flynn, D.L., and Petillo, P.A. (2007). Preparation of 1-pyrazolyl-3-phenylurea p38 MAP Kinase Inhibitors as Antiinflammatory Medicaments. (Application No. 20070191336 A1 20070816), U.S. Patent."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1016\/j.bmcl.2012.05.095","article-title":"Design and synthesis of novel p38\u03b1 MAP kinase inhibitors: Discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety","volume":"22","author":"Arai","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_59","unstructured":"Longshaw, A.I., Fordyce, E.A.F., Onions, S.T., King-Underwood, J., Venable, J.D., and Walters, I. (2015). Preparation of Pyrazolyl-Urea Compounds as p38 MAP Kinase Inhibitors. (Application No. 2015121660), WO Patent."},{"key":"ref_60","unstructured":"Charron, C.E., Ito, K., and Rapeport, W.G. (2011). Ureido-pyrazole Derivatives for Use in the Treatment of Respiratory Disorders. (Application No. 2011158042), WO Patent."},{"key":"ref_61","unstructured":"Charron, C.E., Fenton, R., Crowe, S., Ito, K., Strong, P., Rapeport, G., and Ray, K. (2011). Preparation of Pyrazolylurea Compounds as Hemopoietic Cell Kinase (p59-HCK) Inhibitors for Treatment of Influenza Infection. (Application No. 2011\/070369), WO Patent."},{"key":"ref_62","unstructured":"Longshaw, A.I., Fordyce, E.A.F., Onions, S.T., King-Underwood, J., and Venable, J.D. (2015). Preparation of Aromatic Heterocyclic Compounds as p38 MAP Kinase Inhibitors with Antiinflammatory Activity. (Application No. 2015121444), WO Patent."},{"key":"ref_63","unstructured":"King-Underwood, J., Murray, P.J., Williams, J.G., Buck, I., and Onions, S.T. (2011). Preparation of Pyrazolyl Naphthyl Ureas as p38 MAP Kinase Inhibitors. (Application No. 2011124930), WO Patent."},{"key":"ref_64","unstructured":"King-Underwood, J., Ito, K., Strong, P., Rapeport, W.G., Charron, C.E., Murray, P.J., Williams, J.G., and Onions, S.T. (2011). 1-(5-Pyrazolyl)-3-(1-naphthyl)ureas as Enzyme Inhibitors and their Preparation, Pharmaceutical Compositions and Use in the Treatment of Inflammatory Disorders. (Application No. 2011124923), WO Patent."},{"key":"ref_65","unstructured":"Ito, K., Strong, P., Rapeport, W.G., Murray, P.J., King-Underwood, J., Williams, J.G., Onions, S.T., Joly, K., and Charron, C.E. (2011). Preparation of Pyrazolyl Ureas as p38 MAP Kinase Inhibitors. (Application No. 2010067130), WO Patent."},{"key":"ref_66","unstructured":"Ito, K., Charron, C.E., King-Underwood, J., Onions, S.T., Longshaw, A.I., Broeckx, R., Filliers, W., and Copmans, A. (2013). Preparation of 1-pyrazolyl-3-{4-[(2-anilinopyrimidin-4-yl)oxy]naphththalen-1-yl}ureas as p38 MAP Kinase Inhibitors. (Application No. 2013050757), WO Patent."},{"key":"ref_67","unstructured":"Duffy, L.A., King-Underwood, J., Longshaw, A.I., Murray, P.J., Onions, S.T., Taddei, D.M.A., Williams, J.G., Ito, K., and Charron, C.E. (2014). Preparation of Pyrazole Ureas as p38 MAP Inhibitors. (Application No. 2014033448 A1 20140306), WO Patent."},{"key":"ref_68","unstructured":"Cariou, C.A.M., Charron, C.E., Fordyce, E.A.F., Hamza, D., Fyfe, M.C.T., Ito, K., King-Underwood, J., Murray, P.J., Onions, S.T., and Thom, S.M. (2014). Preparation of Pyrazolyl-Urea Compounds as Kinase Inhibitors for Treatment of Inflammatory Diseases. (Application No. 2014027209), WO Patent."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1021\/jm0704402","article-title":"Synthesis and biological evaluation of N-pyrazolyl-N\u2032-alkyl\/benzyl\/phenylureas: A new class of potent inhibitors of interleukin 8-induced neutrophil chemotaxis","volume":"50","author":"Bruno","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1016\/j.bmc.2009.03.035","article-title":"1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl\/cycloalkyl\/phenyl\/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors","volume":"17","author":"Bruno","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"ref_71","first-page":"39","article-title":"Treatment with 1-(2-hydroxyalkyl)-5-(3-alkyl\/phenyl\/naphthylureido)-1Hpyrazole-4-carboxylic acid ethyl esters abrogates neutrophil migration towards fMLP and CXCL8 via the inhibition of defined signalling pathways","volume":"44","author":"Bertolotto","year":"2014","journal-title":"Eur. J. Clin. Invest."},{"key":"ref_72","unstructured":"Bruno, O., Bondavalli, F., Brullo, C., and Schenone, S. (2009). Ureas Derivatives of 1H-pyrazol-4-carboxylic Acid with Neutrophil Chemotaxis Inhibiting Activity. (Application No. 2033955 A1), EP Patent."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ejmech.2011.11.031","article-title":"N-Aryl-2-phenyl-2,3-dihydro-imidazo[1,2-b]pyrazole-1-carboxamides 7-substituted strongly inhibiting both fMLP-Ome- and IL-8-induced human neutrophil chemotaxis","volume":"47","author":"Brullo","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejphar.2013.07.045","article-title":"Differential inhibition of signaling pathways by two new imidazo-pyrazoles molecules in fMLF-Ome- and IL8-stimulated human neutrophil","volume":"718","author":"Selvatici","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejmech.2017.03.066","article-title":"Design, synthesis and biological evaluation of new pyrazolyl-ureas and imidazopyrazolecarboxamides able to interfere with MAPK and PI3K upstream signaling involved in the angiogenesis","volume":"133","author":"Meta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"108195","DOI":"10.18632\/oncotarget.22598","article-title":"The pyrazolyl-urea GeGe3 inhibits tumor angiogenesis and reveals dystrophia myotonica protein kinase (DMPK)1 as a novel angiogenesis target","volume":"8","author":"Meta","year":"2017","journal-title":"Oncotarget"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s11164-015-2100-8","article-title":"Synthesis of some novel 4-benzothiazol-2-ylbenzoyl-1H-pyrazoles, and evaluation as antiangiogenic agents","volume":"42","author":"Ali","year":"2016","journal-title":"Res. Chem. Intermediat."},{"key":"ref_78","unstructured":"Flynn, D.L., and Petillo, P.A. (2006). Preparation of Pyrazolyl Phenyl Ureas as Enzyme Modulators. (Apllication No. 2006071940 A2 20060706), WO Patent."},{"key":"ref_79","unstructured":"Flynn, D.L., and Petillo, P.A. (2008). Preparation of Pyrazolyl Phenyl Ureas as Enzyme Modulators. (Application No. 20080113967 A1 20080515), U.S. Patent."},{"key":"ref_80","unstructured":"Smith, R., Hatoum-Mokdad, H.N., Cantin, L.D., Bierer, D.E., Fu, W., Nagarathnam, D., Ladouceur, G., Wang, Y., Ogutu, H., and Wilhelm, S. (2007). Pyrazole Urea Compounds Useful in the Treatment of Cancer and their Preparation. (Application No. 2007064872), WO Patent."},{"key":"ref_81","unstructured":"Flynn, D.L., Petillo, P.A., and Kaufman, M.D. (2010). Preparation of Urea Derivatives as Kinase Inhibitors Useful for the Treatment of Myeloproliferative Diseases and Other Proliferative Diseases. (Application No. 7790756 B2 20100907), U.S. Patent."},{"key":"ref_82","unstructured":"Flynn, D.L., Petillo, P.A., and Kaufman, M.D. (2013). Preparation of Heterocyclic Urea Derivatives as Kinase Inhibitors Useful for the Treatment of Myeloproliferative Diseases and Other Proliferative Diseases. (Application No. 2013036232 A2 20130314), WO Patent."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1021\/jm9002928","article-title":"Hybrid Compound Design to Overcome the Gatekeeper T338M Mutation in cSrc","volume":"52","author":"Getlik","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jphotobiol.2017.02.003","article-title":"Synthesis, DNA binding and in-vitro cytotoxicity studies on novel bis-pyrazoles","volume":"168","author":"Indrasena","year":"2017","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1126\/science.1212728","article-title":"A SUMOylation-dependent Transcriptional Subprogram Is Required for Myc-driven Tumorigenesis","volume":"335","author":"Kessler","year":"2012","journal-title":"Science"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.bmcl.2016.01.030","article-title":"Identification of new SUMO activating enzyme 1 inhibitors using virtual screening and scaffold hopping","volume":"26","author":"Kumar","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.mcn.2005.09.007","article-title":"Origin and Evolution of the Trk Family of Neurotrophic Receptors","volume":"31","author":"Comella","year":"2006","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_88","unstructured":"Brandhuber, B.J., Jiang, Y., Kolakowski, G.R., and Winski, S.L. (2014). Pyrazolyl Urea, Thiourea, Guanidine and Cyanoguanidine Compounds as TrkA Kinase Inhibitors and their Preparation. (Application No. 2014078417 A1 20140522), WO Patent."},{"key":"ref_89","unstructured":"Allen, S., Andrews, S.W., Baer, B., Crane, Z., Liu, W., and Watson, D.J. (2015). Preparation of 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TRKA Kinase Inhibitor. (Application No. 2015175788 A1 20151119), WO Patent."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1021\/acschembio.9b00126","article-title":"Deciphering the Allosteric Binding Mechanism of the Human Tropomyosin Receptor Kinase A (hTrkA) Inhibitors","volume":"14","author":"Subramanian","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.bmcl.2017.01.056","article-title":"The juxtamembrane region of TrkA kinase is critical for inhibitor selectivity","volume":"27","author":"Furuya","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_92","unstructured":"Shikano, K., Yamaguchi, H., Horiguchi, T., Yasuo, K., and Hata, K. (2019). Pain Therapeutic or Preventive Containing Fused Heterocycles and Heterocycle-Fused Carbocycles Having TrkA Inhibitory Activity. (Application No. 2019189573), JP Patent."},{"key":"ref_93","unstructured":"Yukimasa, A., Shikano, K., Horiguchi, T., Nakamura, K., Inoue, T., Fujo, M., and Yamaguchi, H. (2019). Pain Treatment and\/or Preventive Agent Containing Nitrogen-Containing Heterocycles Having Tropomyosin Receptor Kinase A (TrkA)-Inhibitory Activity. (Application No. 2019026646), JP Patent."},{"key":"ref_94","unstructured":"Vaidya, A.B., Welsh, W.J., Kortagere, S., and Bergman, L.W. (2009). Mechanism-Based Small Heterocyclic Molecule Parasite Inhibitors. (Application No. 2009065096 A1 20090522), WO Patent."},{"key":"ref_95","unstructured":"Welsh, W.J., Kortagere, S., Bergman, L.W., and Vaidya, A.B. (2013). Mechanism-Based Small-Molecule Parasite Inhibitors. (Application No. 8486987 B2 20130716), U.S. Patent."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10822-006-9077-8","article-title":"Development and application of hybrid structure-based method for efficient screening of ligands binding to G-protein coupled receptors","volume":"20","author":"Kortagere","year":"2006","journal-title":"J. Comput.-Aided. Mol. Des."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1021\/ci100039k","article-title":"Structure-based design of novel small-molecule inhibitors of Plasmodium falciparum","volume":"50","author":"Kortagere","year":"2010","journal-title":"J. Chem. Inf. Model."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nrm1354","article-title":"Biology, structure, and mechanism of P-type ATPases","volume":"5","author":"Kuhlbrandt","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bbabio.2008.12.019","article-title":"P-type ATPases as drug targets: Tools for medicine and science","volume":"1787","author":"Yatime","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.bbamem.2010.07.009","article-title":"Sodium or potassium efflux ATPase a fungal, bryophyte, and protozoal ATPase","volume":"1798","author":"Benito","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.chom.2012.12.006","article-title":"Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials","volume":"13","author":"Spillman","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa1315860","article-title":"Spiroindolone KAE609 for falciparum and vivax malaria","volume":"371","author":"White","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"7761","DOI":"10.1021\/jm400325j","article-title":"Using genetic methods to define the targets of compounds with antimalarial activity","volume":"56","author":"Flannery","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1021\/cb500616x","article-title":"Mutations in the P-Type Cation-Transporter ATPase 4, PfATP4, Mediate Resistance to Both Aminopyrazole and Spiroindolone Antimalarials","volume":"10","author":"Flannery","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/acsinfecdis.6b00078","article-title":"Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase","volume":"3","author":"Hewitt","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10822-011-9420-6","article-title":"Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach","volume":"25","author":"Kortagere","year":"2011","journal-title":"J. Comput.-Aided Mol. Des."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1016\/j.bmcl.2003.09.013","article-title":"Ureas of 5-aminopyrazole and 2-aminothiazole inhibit growth of gram-positive bacteria","volume":"13","author":"Kane","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1087057114548832","article-title":"Identification of potent inhibitors of the Trypanosoma brucei methionyl-tRNA synthetase via high-throughput orthogonal screening","volume":"20","author":"Buckner","year":"2015","journal-title":"J. Biomol. Screen."},{"key":"ref_109","unstructured":"Murray, P.J., Onions, S.T., Williams, J.G., and Joly, K. (2011). Preparation of Pyrido[2,3-b]pyrazine Compounds for Use in Drug Formulations for Treating Inflammation, Respiratory Disorders, and Viral Infections. (Application No. 2011158044 A2 20111222), WO Patent."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrn2834","article-title":"Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease","volume":"11","author":"Luscher","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1124\/mol.107.041053","article-title":"A novel assay of Gi\/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors","volume":"73","author":"Niswender","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1021\/cn400062a","article-title":"ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in mice","volume":"4","author":"Kaufmann","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1021\/acschemneuro.7b00217","article-title":"Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1\/2 Potassium Channel Activators","volume":"8","author":"Wieting","year":"2017","journal-title":"ACS Chem. Neurosci."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/15\/3457\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:52:46Z","timestamp":1760176366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/15\/3457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":113,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["molecules25153457"],"URL":"https:\/\/doi.org\/10.3390\/molecules25153457","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]}}}